Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 23:10:2379-2385.
doi: 10.2147/PPA.S118396. eCollection 2016.

Gender- and age-related treatment compliance in patients with osteoporosis in Germany

Peyman Hadji  1 , Louis Jacob  2 , Karel Kostev  3
Affiliations

Gender- and age-related treatment compliance in patients with osteoporosis in Germany

Peyman Hadji et al. Patient Prefer Adherence. .

Abstract

Aim: The purpose of this study was to analyze treatment compliance in osteoporotic patients treated with osteoporosis medications in Germany.

Methods: Patients included in the analysis had been diagnosed with osteoporosis with or without fractures and started anti-osteoporotic therapy (bisphosphonates, denosumab, or strontium ranelate) between 2011 and 2014 in a general (GP) or orthopedic practice (OP) setting in Germany. Data pertaining to 6,221 individuals followed in GP and 4,044 individuals followed in OP were analyzed retrospectively. The last follow-up was in December 2015. The main outcome measure was the compliance within the one-year period after the index prescription date. Compliance was measured indirectly and was based on the mean possession ratio (MPR). A multivariate logistic regression model was used to determine the association between MPR (dependent variable) and age, gender, type of practice, type of osteoporosis treatment, therapy frequency, and history of fracture (covariates).

Results: The mean age of the study group was 73.3 years, and 13.2% of subjects were men. Regarding type of practice, 60.6% of individuals were followed in GP and 39.4% in OP. Noncompliance was observed in 55.2% of the patients. Patients in the age group ≤60 years were at a higher risk of being noncompliant when compared to those in the age group of 61-70 years. Men and patients who received oral drugs were also more likely to be noncompliant than women and patients who received injectable or intravenous drugs. Finally, therapies that were given every three or six months were associated with a decrease in the risk of noncompliance when compared to weekly therapy, whereas daily and monthly treatments were associated with an increased risk.

Conclusion: Compliance is insufficient in osteoporotic patients treated with osteoporosis medications.

Keywords: Germany; compliance; fracture; osteoporosis treatment; real-world data.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flowchart of osteoporotic patients with anti-osteoporotic therapy in general and orthopedic practices in Germany included in this study. Abbreviation: ICD 10, International Classification of Diseases, Tenth Revision.
Figure 2
Figure 2
Example of the MPR calculation. Abbreviations: MPR, mean possession ratio; BSP, Bisphosphonate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Facts and Statistics. International Osteoporosis Foundation; [Accessed July 18, 2016]. Available from: https://www.iofbonehealth.org/facts-statistics.
    1. Höer A, Seidlitz C, Gothe H, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence. 2009;3:25–30. - PMC - PubMed
    1. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis – for whom and for how long? N Engl J Med. 2012;366(22):2051–2053. - PMC - PubMed
    1. Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26(10):2479–2489. - PMC - PubMed
    1. Hadji P, Klein S, Häussler B, et al. The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. Int J Clin Pharmacol Ther. 2013;51(11):868–872. - PubMed

LinkOut - more resources